Other papers submitted by: Professor Jason Guertin

open access to scientific and medical research

News:

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to User profile » Professor Jason Guertin

Papers published by Professor Jason Guertin:

Review

Methods used to account for caregivers’ sex and gender within studies examining the financial burden of caregivers of children and adolescents : Results from a scoping review

Guertin JR, Gilbert-Ouimet M, Dugas M, Carnovale V, Jalbert L, Svyntozelska O, Demers J, Matteau L, Bergeron F, LeBlanc A

ClinicoEconomics and Outcomes Research 2024, 16:35-53

Published Date: 26 January 2024

Original Research

Highly-accessed

Health-Related Quality of Life of Patients Presenting to the Emergency Department with a Musculoskeletal Disorder

Gagnon R, Perreault K, Guertin JR, Berthelot S, Achou B, Hébert LJ

ClinicoEconomics and Outcomes Research 2022, 14:91-103

Published Date: 19 February 2022

Original Research

Highly-accessed

Issue with Evaluating Costs Over Time in a Context of Medical Guideline Changes: An Example in Myocardial Infarction Care Based on a Longitudinal Study from 1997 to 2018

Villeneuve T, Trudel X, Gilbert-Ouimet M, Leclerc J, Milot A, Sultan-Taïeb H, Brisson C, Guertin JR

ClinicoEconomics and Outcomes Research 2022, 14:11-20

Published Date: 7 January 2022

Original Research

Highly-accessed

Just how much does it cost? A cost study of chronic pain following cardiac surgery

Guertin JR, Pagé MG, Tarride JÉ, Talbot D, Watt-Watson J, Choinière M

Journal of Pain Research 2018, 11:2741-2759

Published Date: 8 November 2018

Original Research

Highly-accessed

Plain language summary

Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada

Tarride JE, Hopkins RB, Burke N, Guertin JR, O'Reilly D, Fell CD, Dion G, Kolb M

ClinicoEconomics and Outcomes Research 2018, 10:127-137

Published Date: 22 February 2018

Original Research

Noteworthy comment: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. The objective of this study was to examine the impact on the ICER of the future introduction of lower cost generic versions of the a new patented drug (NPRx) within the model’s time horizon. ICER estimated within economic evaluations comparing NPRx to generic comparators which ignore the future introduction of lower cost generic versions of the NPRx within the model’s time horizon will tend to be overestimated. Inclusion of this parameter should be considered within future economic evaluations.

Highly-accessed

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

Guertin JR, Mitchell D, Ali F, LeLorier J

ClinicoEconomics and Outcomes Research 2015, 7:497-503

Published Date: 6 October 2015